



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

Pediatric regulatory science, clinical trial networks hold promise for studies

CSDD benchmarks industry experience with pediatric studies initiative

- Pediatric regulatory science and pediatric clinical trial networks are believed to hold the greatest promise for improving pediatric drug development.
- Progress is being made on BPCA and PREA goals.
- Most respondents to a Tufts CSDD survey said pediatric study complexity has increased more than 50% since 2008.
- Patient recruitment/retention and study modifications were identified as the factors most responsible for driving up pediatric study costs.
- Resources dedicated to pediatric studies have increased across most R&D functions.